Table 1. Cardiovascular and global index events by age at baseline.
Reprinted from Rossouw et al. 44 with permission.
| Age Group at Randomization |
P Value for
Trend † |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 50–59y | 60–69y | 70–79y | ||||||||
| No. of Cases | No. of Cases | No. of Cases | ||||||||
| Hormone
Therapy (n=4476) |
Placebo
(n=4356) |
HR
(95% CI) * |
Hormone
Therapy (n=6240) |
Placebo
(n=6122) |
HR
(95% CI) * |
Hormone
Therapy (n=3100) |
Placebo
(n=3053) |
HR
(95% CI) * |
||
| Combined Trials | ||||||||||
| CHD ‡ | 59 | 61 | 0.93
(0.65-1.33) |
174 | 178 | 0.98
(0.79-1.21) |
163 | 131 | 1.26
(1.00-1.59) |
.16 |
| Stroke | 44 | 37 | 1.13
(0.73-1.76) |
156 | 102 | 1.50
(1.17-1.92) |
127 | 100 | 1.21
(0.93-1.58) |
.97 |
| Total
mortality |
69 | 95 | 0.70
(0.51-0.96) |
240 | 225 | 1.05
(0.87-1.26) |
237 | 208 | 1.14
(0.94-1.58) |
.06 |
| Global
index § |
278 | 278 | 0.96
(0.81-1.14) |
717 | 661 | 1.08
(0.97-1.20) |
606 | 528 | 1.14
(1.02-1.29) |
.09 |
| CEE Trial | ||||||||||
|
CEE
(n=1637) |
Placebo
(n=1673) |
CEE
(n=2387) |
Placebo
(n=2465) |
CEE
(n=1286) |
Placebo
(n=1291) |
|||||
| CHD ‡ | 21 | 34 | 0.63
(0.36-1.09) |
96 | 106 | 0.94
(0.71-1.24) |
84 | 77 | 1.13
(0.82-1.54) |
.12 |
| Stroke | 18 | 21 | 0.89
(0.47-1.69) |
84 | 54 | 1.62
(1.15-2.27) |
66 | 52 | 1.21
(0.84-1.75) |
.62 |
| Total
mortality |
34 | 48 | 0.71
(0.46-1.11) |
129 | 131 | 1.02
(0.80-1.30) |
134 | 113 | 1.20
(0.93-1.55) |
.18 |
| Global
index § |
114 | 140 | 0.82
(0.64-1.05) |
333 | 342 | 1.01
(0.86-1.17) |
300 | 262 | 1.16
(0.98-1.37) |
.01 |
| CEE + MPA Trial | ||||||||||
|
CEE + MPA
(n=2839) |
Placebo
(n=2683) |
CEE + MPA
(n=3853) |
Placebo
(n=3657) |
CEE + MPA
(n=1814) |
Placebo
(n=1762) |
|||||
| CHD ‡ | 38 | 27 | 1.29
(0.79-2.12) |
78 | 72 | 1.03
(0.74-1.43) |
79 | 54 | 1.48
(1.04-2.11) |
.70 |
| Stroke | 26 | 16 | 1.41
(0.75-2.65) |
72 | 48 | 1.37
(0.95-1.97) |
61 | 48 | 1.21
(0.82-1.78) |
.56 |
| Total
mortality |
35 | 47 | 0.69
(0.44-1.07) |
111 | 94 | 1.09
(0.83-1.44) |
103 | 95 | 1.06
(0.80-1.41) |
.19 |
| Global
index § |
164 | 138 | 1.10
(0.87-1.38) |
384 | 319 | 1.15
(0.99-1.34) |
306 | 266 | 1.13
(0.95-1.33) |
.96 |
Abbreviations: CEE, conjugated equine estrogens; CHD, coronary heart disease; CI, confidence interval; HR, hazard ratio; MPA, medroxyprogesterone acetate.
*Cox regression models stratified according to prior cardiovascular disease and randornization status in the Dietary modification Trial.
†Test for trend (interaction) using age as continuous (linear) form of categorical coded values. Cox regression models stratified according to active vs placebo and trial, including terms for age and the interaction between trials and age.
‡Defined as CHD death, nonfatal myocardial infarcation, or definite silent myocardial infarction (Novacode 5.1 or 5.2).
§Defined as CHD, stroke, pulmonary embolism, breast cancer, colorectal cancer, endometrial cancer for CEE plus MPA trial only, hip fracture, or death from other causes.